From Nasdaq: 2025-02-17 01:32:55

Bristol Myers Squibb (BMY) released new five-year results from the POETYK PSO trial for Sotyktu (deucravacitinib) in adult patients with moderate-to-severe plaque psoriasis. The safety profile of Sotyktu remained consistent over five years with more than 5,000 patient-years of exposure, showing no new safety concerns. Patients continuously treated with Sotyktu maintained clinical response rates from Year 1 to Year 5, including PASI 75, PASI 90, and sPGA 0/1. Sotyktu, a TYK2 inhibitor, is approved in multiple countries for treating adults with moderate-to-severe plaque psoriasis, potentially becoming an oral standard of care.



Read more at Nasdaq: BMY : New Five-Year Sotyktu Data Show Durable, Safe Response In Moderate-to-Severe Plaque Psoriasis